dr. rini on axitinib for treatment of metastatic renal cell carcinoma
Published 8 years ago • 2K plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
0:38
dr. rini explains the axitinib integration process
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
1:12
dr. rini describes axitinib's and sorafenib's side effects
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc
-
0:53
dr. rini on standards of care for advanced rcc
-
9:57
how to select 1st line therapy for metastatic renal cell cancer?
-
59:55
renal cell carcinoma: past, present, and future
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
0:43
dr. rini on adjuvant immunotherapy in renal cell carcinoma
-
0:43
dr. rini discusses the vegf targeted agent axitinib
-
1:03
dr. rini on managing the toxicity of pembrolizumab plus axitinib in mrcc
-
1:34
dr. rini on pembrolizumab plus axitinib in rcc
-
0:43
dr. rini on the results from his axitinib and sorafenib trial
-
3:30
individualized axitinib dosing for patients with metastatic renal cell carcinoma
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
0:54
dr. rini on sequencing of immunotherapy combinations in rcc
-
3:41
tide-a: avelumab and intermittent axitinib in metastatic renal cell carcinoma
-
0:49
dr. rini describes hypertension as a biomarker in rcc
-
0:59
dr. rini on cytoreductive nephrectomy in rcc
-
8:31
second-line angiogenesis inhibition in metastatic renal cell carcinoma
-
0:56
dr. rini on practice gaps and barriers to optimal care of renal cell carcinoma